Back to Newsroom

Ocata Therapeutics Appoints Dr. Brian Levy to its Board of Directors

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Brian Levy, O.D., M.Sc., has joined Ocata’s Board of Directors. Most recently, Dr. Levy served as Chief Medical Officer of Aerie Pharmaceuticals, Inc.

“Brian has been a widely regarded leader in the pharmaceutical industry for more than two decades, including fifteen years at Bausch + Lomb where he was the Chief Medical Officer and he brings significant drug development and commercialization experience, particularly in ophthalmic products, to Ocata” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “We are pleased that Brian is joining our board to provide his expertise and guidance as we enter our next phase of advanced clinical trials for Dry AMD and Stargardt’s disease with our RPE therapy.”

Click here to read more